Opioid Monitoring in Clinical Settings: Strategies and Implications of Tailored Approaches for Therapy
- PMID: 38892112
- PMCID: PMC11173075
- DOI: 10.3390/ijms25115925
Opioid Monitoring in Clinical Settings: Strategies and Implications of Tailored Approaches for Therapy
Abstract
This review emphasises the importance of opioid monitoring in clinical practice and advocates for a personalised approach based on pharmacogenetics. Beyond effectively managing pain, meticulous oversight is required to address concerns about side effects, specially due to opioid-crisis-related abuse and dependence. Various monitoring techniques, along with pharmacogenetic considerations, are critical for personalising treatment and optimising pain relief while reducing misuse and addiction risks. Future perspectives reveal both opportunities and challenges, with advances in analytical technologies holding promise for increasing monitoring efficiency. The integration of pharmacogenetics has the potential to transform pain management by allowing for a precise prediction of drug responses. Nevertheless, challenges such as prominent pharmacogenetic testing and guideline standardisation persist. Collaborative efforts are critical for transforming scientific advances into tangible improvements in patient care. Standardised protocols and interdisciplinary collaboration are required to ensure consistent and evidence-based opioid monitoring. Future research should look into the long-term effects of opioid therapy, as well as the impact of genetic factors on individual responses, to help guide personalised treatment plans and reduce adverse events. Lastly, embracing innovation and collaboration can improve the standard of care in chronic pain management by striking a balance between pain relief and patient safety.
Keywords: chronic pain; clinical implications; monitoring; opioids; pharmacogenetics.
Conflict of interest statement
The authors declare no conflicts of interest.
Similar articles
-
Fundamental Considerations for Genetically-Guided Pain Management with Opioids Based on CYP2D6 and OPRM1 Polymorphisms.Pain Physician. 2018 Nov;21(6):E611-E621. Pain Physician. 2018. PMID: 30508992 Review.
-
Opioid use disorder in pediatric populations: considerations for perioperative pain management and precision opioid analgesia.Expert Rev Clin Pharmacol. 2024 May-Jun;17(5-6):455-465. doi: 10.1080/17512433.2024.2343915. Epub 2024 Apr 21. Expert Rev Clin Pharmacol. 2024. PMID: 38626303 Free PMC article. Review.
-
Responsible, Safe, and Effective Prescription of Opioids for Chronic Non-Cancer Pain: American Society of Interventional Pain Physicians (ASIPP) Guidelines.Pain Physician. 2017 Feb;20(2S):S3-S92. Pain Physician. 2017. PMID: 28226332
-
The Opioid Crisis and the Future of Addiction and Pain Therapeutics.J Pharmacol Exp Ther. 2019 Nov;371(2):396-408. doi: 10.1124/jpet.119.259408. Epub 2019 Sep 3. J Pharmacol Exp Ther. 2019. PMID: 31481516 Free PMC article. Review.
-
Pharmacogenomics in chronic pain therapy: from disease to treatment and challenges for clinical practice.Pharmacogenomics. 2019 Aug;20(13):971-982. doi: 10.2217/pgs-2019-0066. Pharmacogenomics. 2019. PMID: 31486733 Review.
Cited by
-
A Comprehensive 10-Year Nationwide Pharmacovigilance Surveillance on Antibacterial Agents in Korea: Data Mining for Signal Detection of Trends and Seriousness of Adverse Events.Microorganisms. 2025 Jan 10;13(1):136. doi: 10.3390/microorganisms13010136. Microorganisms. 2025. PMID: 39858904 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical